Varicella-Zoster Virus ORF61 Deletion Mutants Replicate in Cell Culture, but a Mutant with Stop Codons in ORF61 Reverts to Wild-Type Virus  by Cohen, Jeffrey I. & Nguyen, Hanh
Varicella-Zoster Virus ORF61 Deletion Mutants Replicate in Cell Culture, but a Mutant
with Stop Codons in ORF61 Reverts to Wild-Type Virus
Jeffrey I. Cohen1 and Hanh Nguyen
Medical Virology Section, Laboratory of Clinical Investigation, National Institute of Allergy
and Infectious Diseases, NIH, Bethesda, Maryland 20892
Received January 26, 1998; returned to author for revision February 24, 1998; accepted April 16, 1998
Varicella-zoster virus (VZV) ORF61 encodes a phosphoprotein that transactivates VZV promoters. Transfection of cells
with cosmid DNAs, including a cosmid with a large deletion in ORF61, resulted in a VZV ORF61 deletion mutant that was
impaired for growth in vitro and could be partially complemented by growth in neuroblastoma or osteosarcoma cell
lines. Cells infected with the VZV ORF61 deletion mutant expressed normal levels of an immediate-early VZV protein, but
had reduced levels of a late protein and showed abnormal syncytia. Carboxy terminal truncation mutants of VZV ORF61
protein have a transrepressing phenotype and inhibit the infectivity of cotransfected wild-type viral DNA. Transfection
of cells with cosmid DNAs, including a cosmid with stop codons that should result in an ORF61 truncation mutant
expressing a transrepressing protein that retains the RING finger domain, resulted in a viral genome which reverted
back to the wild-type sequence. BAL-31 exonuclease was used to produce deletions at the site of the stop codons in
ORF61 of the cosmid, resulting in loss of the RING finger domain. Transfection of tissue culture cells with the ORF61
BAL-31 deletion mutants and other cosmid DNAs yielded viable viruses. Thus, while deletion mutants lacking the RING
finger domain of ORF61 replicate in cell culture, a mutant with stop codons that retains this domain could not be
propagated and reverted to wild-type virus.
INTRODUCTION
Varicella-zoster virus (VZV) is a member of the al-
phaherpesvirus subfamily of herpesviruses. Other
members include herpes simplex virus (HSV), pseudo-
rabies virus (PRV), and bovine herpesvirus (BHV). Each
of these viruses has a homolog of the ORF61 transac-
tivator protein present in VZV (Cheung, 1991; Perry et
al., 1986; Wirth et al., 1992). This family of proteins all
share a RING finger domain, also termed the C3HC4
motif, containing a similar pattern of cysteine and
histidine residues near their amino terminus (Free-
mont et al., 1991; Moriuchi et al., 1994). RING finger
domains have been shown to bind zinc and are
thought to be important for protein–protein interac-
tions (Saurin et al., 1996).
ORF61 encodes a 62- to 65-kDa phosphorylated pro-
tein that localizes to the nucleus of infected cells with
nucleolar exclusion (Stevenson et al., 1992). The RING
finger domain of ORF61 is located between amino acids
19 and 57 (Barlow et al., 1994). The amino terminal region
of ORF61 is more highly phosphorylated than the carboxy
terminal region (Stevenson et al., 1992). The carboxy
portion of the protein contains sequences necessary for
localization in the nucleus.
VZV ORF61 protein transactivates VZV immediate-early
(IE) and putative early gene promoters in transient ex-
pression assays. In addition, ORF61 protein transacti-
vates HSV IE, early, and latency-associated transcript
gene promoters as well as other viral promoters in tran-
sient expression assays (Moriuchi et al., 1993). VZV
ORF61 protein can repress or transactivate the function
of VZV transactivators (ORF4, ORF62) on VZV gene pro-
moters, depending on the transfection conditions and
cell lines used (Moriuchi et al., 1993; Nagpal and Os-
trove, 1991; Perera et al., 1992). A carboxy terminal trun-
cation mutant of ORF61 protein that retains the RING
finger domain acts as transrepressor and as a dominant
negative mutant in the presence of full-length ORF61
protein (Moriuchi et al., 1994). Transient expression of
VZV ORF61 protein enhances the infectivity of VZV and
HSV-1 DNA (Moriuchi et al., 1993).
VZV ORF 61 protein is homologous to HSV ICP0 (Perry
et al., 1986) and can functionally complement an ICP0
deletion mutant of HSV-1 (Moriuchi et al., 1992). ICP0 is
not essential for growth of HSV-1 in cell culture; however,
deletion of the gene results in marked impairment of
growth after infection at a low multiplicity of infection (Cai
and Schaffer, 1992; Chen and Silverstein, 1992; Stow and
Stow, 1986). Furthermore, cells infected with HSV-1 mu-
tants that do not express ICP0 show decreased levels of
HSV-1 early and late proteins, decreased levels of the
immediate-early ICP27 protein, and normal levels of the
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immediate-early ICP4 protein (Cai and Schaffer, 1992;
Chen and Silverstein, 1992).
To determine whether VZV ORF61 is essential for
growth in cell culture and to study its role in regulating
VZV gene expression during infection in vitro, we con-
structed VZV mutants that were deleted for ORF61. VZV
with a large deletion in ORF61 was impaired for growth in
vitro and partially complemented when grown in neuro-
blastoma and osteosarcoma cell lines. In contrast, an
ORF61 mutant with stop codons that retained the RING
finger domain could not be propagated and reverted to
wild-type virus.
RESULTS
VZV ORF61 is not essential for replication of virus in
cell culture
To produce a virus that does not express VZV ORF61
protein, cosmid MstII A-61D was constructed, which has
a large deletion in the ORF61 gene (Fig. 1). Plasmid
pNotB, which overlaps cosmids MstIIA and MstII B, was
also constructed, since the previously described cosmid
NotI BD (Cohen and Seidel, 1993) contains ORF61 and
would have interfered with attempts to delete this gene.
Initial transfections of MeWo cells with the large ORF61
deletion mutant cosmid along with pNotB, cosmids NotI
A and MstII B did not yield infectious virus. Therefore cell
lines containing ORF61 driven by the its endogenous
promoter were constructed. Individual cell clones were
transfected with cosmids without prior screening.
Transfection of one of these cell lines, M61-22-2, with
VZV plasmid pNotB, cosmids NotI A, MstII B, and MstII A
or MstII A-61D yielded infectious VZV. Plaques were first
detected 9 days after transfection with pNotB and cos-
mids NotI A, MstII B, and MstII A and 20 days after
transfection, CPE was observed in M61-22-2 cells trans-
fected with pNotB, NotI A, MstII B, and MstII A-61DA or
MstII A-61DB.
FIG. 1. Construction of VZV ORF61 mutants. The VZV genome is 124,884 bp in length (line 1) and contains terminal repeat (TRL, TRS) unique (UL,
US), and internal repeat (IRL, IRS) DNA segments (line 2). The NotI and MstII restriction fragments contained in the parental plasmid and cosmids are
shown (lines 3,4). The nucleotide positions are based on the prototype Dumas strain of VZV (Davison and Scott, 1987). Cosmid MstIIA-61S contains
stop codons in all three reading frames after the 79th codon of ORF61 (line 5). Cosmid MstIIA-61dA has stop codons after amino acid 13 and deletion
of amino acids 14 to 127 (line 6). Cosmid MstII A-61dB has stop codons after amino acid 13 and deletion of amino acids 14 to 100 (line 7). Cosmid
MstIIA-61D has a deletion beginning 26 bp upstream from the start codon and ending at amino acid 453 of ORF61 (line 8). Two identical, independent
cosmid clones, MstIIA-61DA and MstIIA-61DB, were used to construct viruses with a large deletion in ORF61.
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To determine whether VZV deleted for ORF61 could
grow on MeWo cells, VZV obtained from the transfection
using cosmid MstII A-61DA or MstII A-61DB was propa-
gated in M61-22-2 cells and cell-free virus was obtained
by sonicating infected cells. MeWo cells were infected
with cell-free virus and CPE was noted. The resulting
viruses were termed VZV ROka61DA and ROka61DB.
Subsequent experiments were performed using these
viruses grown in MeWo cells. Further experiments indi-
cated that VZV ROka61DA or ROka61DB could be gener-
ated by direct transfection of cosmids into MeWo cells.
Transfection of MeWo cells with pNotB, NotI A, MstII B,
and MstII A-61DA or MstII A-61DB resulted in CPE 19 or
18 days after transfection, respectively.
Southern blots were performed to verify that the VZV
ORF61 mutants had the expected genome structure. Viral
DNA was prepared and digested with BamHI. Southern
blot analysis of a BamHI digest probed with a BsmI
fragment from the ORF61 region showed a 10.6-kb
BamHI B fragment in VZV ROka and a 9.3-kb fragment in
ROka61DA or ROka61DB due to the large deletion in the
ORF61 gene (Fig. 2A). An additional band of 1.9 is present
due to hybridization of the probe [which contains a por-
tion of the IRS (internal repeat short) sequence] with the
TRS terminal repeat short sequence.
To determine that cells infected with the VZV ORF61
deletion mutant viruses do not express ORF61 protein,
lysates were obtained from cells infected with these
viruses and immunoblotted using a rabbit antibody to
ORF61 protein. Cells infected with parental (ROka) VZV
expressed a 63-kDa protein corresponding to ORF61
protein, while cells infected with VZV ROka61DA or
ROka61DB did not produce the protein (Fig. 3A). To verify
that each of the lysates was obtained from VZV-infected
cells, another aliquot of each lysate was immunoblotted
using murine monoclonal antibody to VZV gE. Each of the
VZV-infected cell lysates expressed gE (Fig. 3B).
VZV with stop codons in ORF61, and predicted to
express a transrepressing protein, reverts to wild-
type virus
To further characterize the role of ORF61 in the context
of virus infection, two additional cosmids, MstII A-61SA
and MstII A-61SB (Fig. 1), were constructed in which stop
codons were inserted into the ORF61 gene after the 79th
codon. VZV produced from the cosmids with stop codons
in ORF61 would be expected to produce a carboxy-
truncated form of ORF61 protein containing the RING
finger domain. Prior experiments have shown that trun-
cation mutants of VZV ORF61 protein containing the
RING finger domain have a transrepressing phenotype
and inhibit the infectivity of transfected VZV DNA (Moriu-
chi et al., 1994). Thus, virus with a carboxy terminal
truncation in ORF61 might be more difficult to isolate
than virus deleted for ORF61. Multiple transfections of
MeWo cells with pNotB, VZV cosmids NotI A, MstII B, and
MstII A-61SA or MstII A-61SB failed to yield virus.
To further evaluate whether carboxy truncation mu-
tants of ORF61 protein containing the RING finger do-
main inhibit the ability to produce infectious VZV, cosmid
MstII A-61SA was linearized with AscI, located in the
oligonucleotide containing the stop codons, and BAL-31
exonuclease was used to create small deletions in the
cosmid resulting in cosmids MstII A-61dA and MstII
A-61dB (Fig. 1). VZV produced from these cosmids would
FIG. 2. Southern blots of virion DNAs from VZV ORF61 mutants. Virion DNA was digested with BamHI and probed with a BsmI fragment from the
ORF61 region (A,D). Virion DNA was also digested with NsiI (B,E) or BamHI and AscI (C) and hybridized with the BsmI fragment.
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be expected to express only the first 13 amino acids of
ORF61 without the RING finger domain and not have a
transrepressing phenotype. While initial transfections of
MeWo cells with these cosmids did not yield virus, trans-
fection of M61-22-2 cells with pNotB, NotI A, MstII B and
MstII A-61dA, or MstII A-61dB resulted in CPE 19 days
and 20 days after transfection, respectively. Similarly,
transfection of M61-22-2 cells with the pNotB, NotI A,
MstII B, and MstII A-61SA or MstII A-61SB resulted in
CPE 22 days and 28 days after transfection, respectively.
In order to verify whether viruses obtained from the
cosmids with the stop codons and small deletions could
grow in MeWo cells, two clones each of VZV ROka61d
and ROka61S were propagated in M61-22-2 cells, cell-
free viruses were obtained by sonicating infected cells,
and CPE was noted after MeWo cells were infected with
the cell-free viruses. Subsequent experiments were per-
formed using virus grown in MeWo cells. Additional ex-
periments showed that transfection of MeWo cells with
pNotB, NotI A, MstII B, and MstII A, MstII A-61dA, or MstII
A-61dB resulted in CPE 9, 19, and 18 days after transfec-
tion, respectively. Virus could not be obtained after trans-
fection of MeWo cells using cosmid MstII A-61SA or
MstII A-61SB despite multiple attempts.
Southern blots of viral DNA cut with BamHI and
probed with a BsmI probe (Fig. 2A) showed a slight
decrease in size of the BamHI B fragment in VZV
ROka61d, compared with ROka, due to the 0.3-kb dele-
tion in ORF61. Digestion of VZV ROka61dA or ROka61dB
with NsiI resulted in loss of 4.0 and 2.1 bands, with new
fragments of 5.75 or 5.8 due to the deletion of an NsiI site
in VZV ORF61dA or ORF61dB, respectively (Fig. 2B). (The
2.1-kb band is not visible in the exposure shown). A
second band of 3.4 kb was also present due to hybrid-
ization of the probe (which contains a portion of the IRS
sequence) with the TRS terminal repeat short sequence.
Digestion of ROka61SA with BamHI and AscI should
cut the 10.6-kb BamHI B fragment into two fragments of
7.9 and 2.7 kb, due to the oligonucleotide that contains
an AscI site that was inserted into the MstII A-61S cos-
mid. However, only the 10.6-kb band (and the 1.9-kb band
as described for Fig. 2A) was seen, indicating that the
AscI site had been lost (Fig. 2C). Similar findings were
also noted with ROka61SB. Nucleotide sequencing of
PCR products from ROka61SA and ROka61SB indicated
that the inserted oligonucleotide had been lost at this
site and wild-type sequence was present in its place.
Immunoblots of cells infected with VZV ROka61dA and
ROka61dB did not express ORF61 protein (Fig. 3A); how-
ever, these cells did express VZV gE (Fig. 3B), verifying
that they were infected with VZV.
Construction of rescued viruses in which the ORF61
deletion has been restored
To verify that growth properties of the ORF61 deletion
mutants were solely due to the lack of expression of
ORF61 and not due to a mutation at an additional site, the
deletions were repaired with a wild-type ORF61 gene.
MeWo cells were cotransfected with ROka61dA or
ROka61DA virion DNA and a plasmid containing ORF61
and flanking sequences. Virus was obtained in MeWo
cells, and cell-free virus was prepared and used to infect
schwannoma cells. Schwannoma cells were used to
select rescued virus from the background of ORF61 de-
leted virus, since the latter virus grows to very low titers
in these cells (see below). Virus was subsequently pas-
saged four times in schwannoma cells and ROka61dAR
and ROka61DAR were isolated.
FIG. 3. Immunoblot of protein extracts from cells infected with VZV ORF61 mutants. Melanoma cells inoculated with VZV ROka-infected cells
express a protein of 63-kDa that reacts with a rabbit antibody to VZV ORF61. Cells infected with ORF61 mutants do not contain the 63 kDa ORF61
protein (A), while cells infected with the ORF61 rescued viruses express this protein (C). Cells infected with VZV ROka, ORF61 mutants or
ORF61-rescued viruses express proteins that react with a monoclonal antibody to VZV gE (B,D). Numbers indicate molecular masses of proteins in
kilodaltons.
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To verify that the ORF61 gene was restored in
ROka61DAR, viral DNA was cut with BamHI and probed
with a BsmI fragment from the ORF61 region. Viral DNA
from ROka61DAR and ROka contained a 10.6-kb BamHI B
fragment, while the ROka61DA showed the 9.3-kb frag-
ment corresponding to the deletion in the ORF61 gene
(Fig. 2D). To ensure that the ORF61 gene was restored in
ROka61dAR, virion DNA was cut with NsiI and probed
with the BsmI fragment. ROka61dAR and ROka resulted
in 4.0-, 3.4-, and 2.1-kb fragments, and the 5.75-kb band
associated with the deletion in ROka61dA was absent
(Fig. 2E).
To ascertain that ORF61 protein was expressed in
cells infected with the rescued ORF61 mutant viruses,
lysates from cells infected with VZV ROka, ROka61DAR,
ROka61dAR, and ROka61DA were immunoblotted using
antibody to ORF61 protein. Cells infected with VZV ROka,
ROka61DAR, and ROka61dAR expressed a 63-kDa pro-
tein corresponding to ORF61, while cells infected with
ROka61dA did not produce the protein (Fig. 3C). Immu-
noblotting with antibody to VZV gE showed that each of
the VZV-infected cell lysates contained gE (Fig. 3D).
VZV unable to express ORF61 protein is impaired for
growth in cell culture
MeWo cells were infected by plating them together
with cells containing VZV ROka, ROka61DA, ROka61DB,
ROka61dA, or ROka61dB and plaque sizes were com-
pared after 7 days. Cells infected with the ORF61 VZV
mutants produced much smaller plaques than those
with VZV ROka. The mean diameter of plaques (6 the
standard deviation) after infection of MeWo cells with
cells containing VZV ROka was 0.62 6 0.17 mm, while
the mean size of plaques produced by VZV ROka61dA
was 0.15 6 0.09 mm and for ROka61dB was 0.13 6 0.07
mm. The mean size of plaques produced by VZV
ROka61DA was 0.21 6 0.09 mm and by ROka61DB was
0.16 6 0.06 mm. The mean plaque size of each of the
ORF61 deletion mutants was significantly different
(P , 0.01) from the mean size of plaques produced by
VZV ROka.
To further determine whether deletion of ORF61 im-
pairs the ability of VZV to grow in vitro, we measured
production of VZV ROka and the ORF61 deletion mutants
during a 5-day growth analysis. MeWo cells were inoc-
ulated with virus-infected cells and the cells were har-
vested at various time points and the titer of virus was
determined. On the first day after infection the titer of VZV
ROka increased, while the titer of ROka61d or ROka61D
declined (Fig. 4A). A difference in growth persisted
throughout the growth analysis. Thus, both the plaque
morphologies and growth curves indicated that the ab-
sence of ORF61 impairs growth of VZV. The VZV ORF61
mutants grew to similar titers in M61-22-2 cells (Fig. 4B)
and the peak titer of the ORF61 mutants was similar in
MeWo and M61-22-2 cells.
FIG. 4. Growth curves of VZV ROka and ORF61 mutants in melanoma (A), M61-22-2 (B), schwannoma (C), Vero (D), osteosarcoma (E), and
neuroblastoma (F) cells. Cells were inoculated with VZV-infected cells, aliquots were harvested on days 1 to 5 after infection, and the titer of the virus
was determined by plating on melanoma cells. Day 0 is the titer of virus in the input inocula.
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VZV unable to express ORF61 protein is partially
complemented by growth in neuroblastoma and
osteosarcoma cell lines
HSV ICP0 mutants can be complemented by growth in
the human osteosarcoma U2OS cell line (Yao and Schaf-
fer, 1995). Therefore, we analyzed the plaque morpholo-
gies of the VZV ORF61 mutants on a number of cell lines
to look for complementation. Compared with parental
virus, the plaque sizes of the VZV ORF61 mutants were
smallest in human schwannoma and largest in human
osteosarcoma and neuroblastoma cell lines. Growth
analysis showed that the VZV ORF61 mutants grew to
very low titers in the schwannoma cell line, never reach-
ing the titer of the input inocula (Fig. 4C). Similarly,
the VZV ORF61 mutants grew to low titers in Vero cells
(Fig. 4D).
To verify that the growth impairment of the ORF61
mutants in MeWo and schwannoma cells was due to the
deletion in ORF61 and not to a mutation elsewhere in the
genome, the growth of the ORF61-rescued viruses were
analyzed in these cell lines. ROka61DAR and ROka61dAR
grew to titers similar to those of the parental ROka virus
in both MeWo (Fig. 5A) and schwannoma (Fig. 5B) cells.
The VZV ORF61 mutants were partially complemented
by growth in U2OS cells (Fig. 4E). While the titer of the
ORF61 mutants was lower on the first day after infection
than the input inoculum, the ORF61 mutant viruses grew
to within 0.5 log of the maximum titer of the parental
virus. Surprisingly, the VZV ORF61 mutants grew to the
highest titers in human neuroblastoma cells (Fig. 4F).
Like the growth in U2OS cells, the ORF61 mutants also
grew in human neuroblastoma cells to within 0.5 log of
the maximum titer of the parental virus.
Since the VZV ORF61 mutants were complemented by
the neuroblastoma cell line, we tested the ability of this
cell line to complement the growth of an HSV-1 ICP0 null
mutant [7134 (Cai and Schaffer, 1989)]. HSV-1 7134 pro-
duced 16-fold more plaques on the neuroblastoma cell
line than on Vero cells (Table 1). The ICP0 mutant was
only partially complemented by this cell line, since the
titer of virus produced was still well below that obtained
with wild-type HSV-1 on any of the cell lines. While the
HSV ICP0 null mutant produced similar numbers of
plaques on melanoma cells as on Vero cells, the ICP0
mutant produced 200-fold more plaques on osteosar-
coma cells. Thus, while the VZV ORF61 and HSV-1 ICP0
mutants were both complemented by neuroblastoma
and osteosarcoma cells, the VZV mutant was comple-
mented more by the neuroblastoma cells, while the HSV
mutant more by osteosarcoma cells.
Cells infected with VZV ORF61 mutants show
abnormal syncytia formation
Infected MeWo cells were examined by immunofluo-
rescent microscopy to compare CPE induced by parental
and ORF61 mutant viruses. MeWo cells were infected
with parental (ROka), ORF61 mutant, and ORF61-restored
VZV and stained with BODIPY FL ceramide that localizes
to the Golgi apparatus. Cells infected with VZV ROka
showed large syncytia with a central Golgi complex
surrounded by multiple nuclei (Fig. 6A), while cells in-
fected with either VZV ROka61DA or ROka61dA showed a
pattern of abnormal syncytia with nuclei distributed in a
disorganized pattern around the central Golgi complex
(Figs. 6B and 6C). Cells infected with VZV in which the
FIG. 5. Growth of VZV with the ORF61 deletions restored in melanoma (A) and schwannoma (B) cells. VZV growth analysis was performed as
described in the legend to Fig. 4.
TABLE 1
Titration of HSV-1 Wild-Type (KOS) and ICP0 Null Mutant (7134)
on Cell Lines
Cell line
KOS titer
(107 PFU/ml)
Fold
increasea
7134 titer
(PFU/ml)
Fold
increasea
Vero 5.1 1.0 4.2 3 104 1.0
MeWo 4.9 0.96 3.6 3 104 0.86
SK-N-SH 4.3 0.84 6.5 3 105 16
U2OS 3.6 0.71 8.3 3 106 200
a Ratio of virus titer on the indicated cell line to the titer on Vero cells.
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ORF61 gene was restored, ROka61DAR, showed syncytia
surrounded by multiple nuclei (Fig. 6D), similar to that
seen with parental virus.
VZV unable to express ORF61 protein shows reduced
expression of a VZV late gene, but not an immediate-
early gene
Cells infected with HSV deleted for ICP0, the ho-
molog of VZV ORF61, express normal levels of the
immediate-early protein ICP4, but reduced levels of
late proteins compared with cells infected with wild-
type HSV (Cai and Schaffer, 1992; Chen and Silver-
stein, 1992). To determine whether cells containing
ORF61 deletion mutants show similar changes in lev-
els of expression of VZV proteins, melanoma cells
were infected with parental (ROka) and ORF61-deleted
(ROka61dA, ROka61DA) viruses and immunoprecipita-
tions were performed using antibodies against the
ORF62 immediate-early protein and a putative late
protein (gE). Cells infected with ORF61 deletion mu-
tants expressed ORF62 protein at levels similar (within
75%) to those seen in cells infected with parental virus
(Fig. 7A). In contrast, cells infected with the ORF61
mutants expressed gE at much lower levels (,40%)
than those obtained with parental virus (Fig. 7B). Thus,
cells infected with VZV deleted for ORF61 show levels
of expression of immediate-early and late proteins
similar to those seen for cells infected with HSV lack-
ing ICP0.
DISCUSSION
We have shown that ORF61 deletion mutants of VZV
are impaired for replication in cell culture, while an
ORF61 stop codon mutant that retains the RING finger
domain reverts to wild-type virus. The ORF61 mutant with
stop codons would be expected to express only the first
FIG. 6. Syncytia formation in cells infected with parental and ORF61 deletion mutants. MeWo cells were infected with VZV ROka (A), ROka61DA (B),
ROka61dA (C), or ROka61DAR (D) and stained with BODIPY fluorescein ceramide. Asterisks indicate syncytia.
FIG. 7. Immunoprecipitations of protein extracts from cells infected
with parental and VZV ORF61 deletion mutants. Cells infected with VZV
ROka, ROka61dA, or ROka61DA express similar levels of the 175-kDa
ORF62 protein (A), while cells infected with ROka61dA or ROka61DA
express less gE (B) than cells infected with ROka. Numbers below the
lanes indicate ratio of the intensity of the band (arrowhead) in cells
infected with the ORF61 mutant virus to the intensity of the band for
VZV ROka.
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79 amino acids of the ORF61 protein. Prior experiments
showed that a plasmid expressing a similar portion of
ORF61 (amino acids 1–80), which includes the RING
finger domain, has a transrepressing phenotype when
cotransfected with a reporter plasmid containing the VZV
ORF62 promoter (Moriuchi et al., 1994). Other carboxy
terminal truncation mutants of ORF61 protein that retain
the RING finger domain also have a transrepressing
phenotype and reduce the infectivity of VZV virion DNA
(Moriuchi et al., 1994). VZV ROka61S was expected to
produce a truncated ORF61 protein that was predicted to
impair virus replication. Multiple attempts in both mela-
noma and M61-22-12 cells to produce infectious VZV
ROka61S with the expected genome were unsuccessful;
two of the transfections yielded a virus whose genome
reverted back to the wild-type virus. Since virus derived
from transfection with a cosmid that should result in a
truncated ORF61 had a full-length ORF61, either the in-
serted oligonucleotide was deleted or ORF61 DNA
present in the M61-22-2 cell line recombined with the
ROka61S viral or MstII A-61S cosmid DNA to restore the
wild-type sequence. Thus, ROka61S is either unable to
grow or is highly impaired for growth, and the genome
reverts to the wild-type sequence.
The carboxy-truncated form of HSV-1 ICP0, the ho-
molog of ORF61 protein, has also been shown to have a
transrepressing phenotype (Weber et al., 1992; Weber
and Wigdahl, 1992) and much of the region correspond-
ing to the portion of ICP0 required for maximum transre-
pression (Spatz et al., 1996) would also be present in
ROka61S. The amino termini of both VZV ORF61 protein
and HSV ICP0 contain a RING finger domain and can
function as dominant negative transrepressing mutants
(Weber and Wigdahl, 1992; Moriuchi et al., 1994). The
amino terminus of HSV ICP0 has been shown to func-
tionally substitute for the amino terminus of VZV ORF61
protein in transient expression assays (Moriuchi et al.,
1994).
While the VZV and HSV-1 truncation mutants behave
similarly in transient transfection assays, recombinant
viruses containing these proteins have very different
phenotypes. Although we were unable to obtain an
ORF61 truncation mutant containing the RING finger do-
main, a recombinant HSV which overexpresses a trans-
repressing ICP0 truncation mutant has been constructed
and replicates at levels similar to those seen with the
ICP0 null mutant virus (Spatz et al., 1997). Unlike ORF61,
ICP0 is spliced and aberrant or alternative splicing can
result in truncated mRNAs (Carter and Roizman, 1996). A
carboxy terminal-truncated protein that has trans-
repressing activity (Weber and Wigdahl, 1992) has been
detected in HSV-infected cells in vitro (Everett et al.,
1993). Thus, unlike HSV ICP0, a carboxy-truncated form
of ORF61 would not normally be expected in VZV-infected
cells.
Cells infected with VZV ORF61 deletion mutants ex-
pressed levels of VZV ORF62 protein similar to those
expressed by cells infected with parental virus; however,
cells infected with the mutants expressed much lower
amounts of VZV gE. Previous studies showed that ORF61
protein can transactivate VZV immediate-early and puta-
tive early promoters (Moriuchi et al., 1993). The ability of
cells infected with the ORF61 mutants to express high
levels of ORF62 protein indicates that ORF61 protein is
not necessary for expression of this immediate-early
gene in vitro. ORF61 protein, however, might be impor-
tant for expression of this gene in vivo, such as during
reactivation from latency.
Cells infected with the VZV ORF61 mutants showed
abnormal formation of syncytia. Since ORF61 protein is
required for high-level expression of gE, the dysregu-
lation of gE (and perhaps other glycoproteins as well)
may be responsible for the disorganized syncytia. A
prior study using a VZV mutant that does not express
VZV gI that results in abnormal processing of gE also
showed abnormalities in syncytia formation (Mallory
et al., 1997).
The VZV ORF61 deletion mutant viruses grew to very
low titers in human schwannoma and Vero cells. In
both cell lines the titer of ROka61D or ROka61d never
exceeded the titer of the input inoculum. In schwan-
noma cells the maximum titer of the deletion mutants
was .2 logs lower than that obtained with the paren-
tal virus. Schwann cells are the equivalent in the
peripheral nervous system of satellite cells (Moses,
1976). VZV RNA has been detected in satellite cells of
humans (Croen et al., 1988). Therefore, the marked
growth impairment of VZV deleted for ORF61 suggests
that this virus might be especially impaired for reacti-
vation from latency.
The VZV ORF61 mutants were partially complemented
by growth in human osteosarcoma and neuroblastoma
cell lines. Yao and Schaffer (1995) showed that the U2OS
osteosarcoma cell line could complement the growth of
an HSV ICP0 mutant. We found that neuroblastoma cells
could also partially complement the HSV ICP0 mutant.
The VZV ORF61 deletion mutants grew to the highest
titers in neuroblastoma cells. These data suggest that
neuroblastoma and osteosarcoma cell lines may ex-
press a protein(s) that can partially substitute for the
function of the ORF61 protein.
In summary we have shown that an ORF61 mutant
with stop codons that retains the RING finger domain
reverts to wild-type virus, while virus deleted for ORF61 is
impaired for growth in cell culture. Since deletion of
ICP0, the homolog of ORF61, reduces the efficiency of
establishment and reactivation of HSV-1 latency in mice
(Cai et al., 1993; Leib et al., 1989), future studies using
VZV deleted for ORF61 will address the role of the protein
in latency of VZV in animal models.
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MATERIALS AND METHODS
Cells and viruses
MeWo cells, derived from a human melanoma and
kindly supplied by Charles Grose, were used for trans-
fections and propagation of virus. The attenuated Oka
strain of VZV was the source for the cosmids used to
derive recombinant VZV (Takahashi et al., 1975). HSV-1
7134, a gift from Priscilla Schaffer, is an ICP0 null mutant
(Cai and Schaffer, 1989). Human schwannoma cells
(ST88-14) were a gift from Cynthia Morton (Reynolds et
al., 1992) and Vero, human U2OS osteosarcoma, and
human SK-N-SH neuroblastoma cells were obtained
from the American Type Culture Collection.
A MeWo cell line containing the ORF61 gene was
constructed by inserting a HindIII fragment [VZV nu-
cleotides 102,110–106,741 (Davison and Scott, 1986)]
from VZV cosmid MstIIA (Cohen and Seidel, 1993) into
the Bst1107I site of plasmid pSV2neo (Southern and
Berg, 1982). The resulting plasmid pSV2neo-ORF61
contains the G418 resistance gene driven by the sim-
ian virus 40 early promoter and the VZV ORF61 gene
with its polyadenylation sequence and endogenous
promoter (Nagpal and Ostrove, 1991). Plasmid pSV2neo-
ORF61 was linearized with AatII and MeWo cells were
transfected with the plasmid using the calcium phosphate
procedure. The cells were treated with trypsin after 2 days
and plated onto 100-mm-diameter dishes, and the next day
G418 (geneticin; Life Technologies, Inc., Grand Island, NY)
was added at 400 mg/ml. After 7 days the concentration of
G418 was reduced to 250 mg/ml and individual colonies
were isolated and amplified.
Cosmids and plasmids
Cosmids VZV NotI A, NotI BD, MstII A, and MstII B
encompass the entire VZV genome and can recombine
after transfection of cells to produce recombinant VZV
(Cohen and Seidel, 1993). The VZV ORF61 open read-
ing frame is located between VZV nucleotides 103,085
and 104,485 in cosmid VZV MstII A. Three strategies
were used to construct mutations in VZV ORF61. First,
stop codons were engineered into the ORF61 gene. A
partial digest of cosmid MstII A was performed using
ApaLI, which cuts both the VZV DNA insert of the
cosmid at nucleotide 104,246 and the cosmid vector
(Fig. 1). The partially cut cosmid DNA was separated
from uncut and multiply cut cosmid by pulsed-field gel
electrophoresis and blunted with the large (Klenow)
fragment of DNA polymerase I, and a double-stranded
oligonucleotide, TAGCTAGGCGCGCCTAGCTA, was in-
serted into the ApaLI site. This oligonucleotide con-
tains stop codons in all three open reading frames and
an AscI restriction site. Two cosmids, VZV MstII
A-61SA and MstII A-61SB, were selected. These cos-
mids contain stop codons after amino acid 79 of
ORF61. Both cosmids were sequenced to verify that
the oligonucleotide had been inserted at the correct
site.
Second, small deletions were engineered into the 59
end of the ORF61 gene. Cosmid VZV MstII-61SA was
cut with AscI, digested with BAL-31 exonuclease, and
blunted with T4 DNA polymerase, and the oligonucle-
otide containing stop codons TAGCTAGGCGCGC-
CTAGCTA was inserted. Two cosmids, VZV MstII
A-61dA and MstII A-61dB, were selected. Sequencing
showed that cosmid MstII A-61dA has a deletion from
VZV nucleotides 104,105 to 104,445 resulting in stop
codons after amino acid 13 and deletion of amino
acids 14 to 127. Cosmid MstII A-61dB has a deletion
from VZV nucleotides 104,187 to 104,445 resulting in
stop codons after amino acid 13 and deletion of amino
acids 14 to 100.
Third, cosmid VZV MstII A was partially digested with
HpaII using the recA-assisted restriction endonuclease
cleavage procedure (Ferrin and Camerini-Otero, 1991).
Two single-stranded 60-base oligonucleotides, CTTGTT-
TGGAATACCTTTACCCGCTTTACCGGCAGAGCTTTTT-
TTGGTAAGGTGTTTCAG and ATGGTAACAACTGGCTG-
TATTCTAATGTCCGGGCATCCAAACACGTAGCAGAACTG-
CCAT centered around the HpaII sites at nucleotides
103,125 and 104,512 of VZV (Davison and Scott, 1986),
were annealed to cosmid VZV MstII A with Escherichia
coli recA as previously described (Heineman and Cohen,
1994). HpaII methylase and S-adenosylmethionine were
added to methylate the remaining HpaII sites in the
cosmid and the DNA–recA complexes were dissociated
by heating to 65°C. After precipitation, the DNA was
digested with HpaII, releasing the 1.4-kb fragment be-
tween the two unmethylated HpaII sites. The large DNA
fragment, lacking most of the ORF61 gene, was extracted
with phenol and precipitated, and the ends were ligated
together. The DNA was packaged and inserted into E.
coli, and two cosmids, VZV MstII A-61DA and MstII
A-61DB were selected. These cosmids contain a deletion
beginning 26 bp upstream from the start codon of ORF61
and ending at amino acid 453 of ORF61. Both cosmids
were sequenced to verify that the deletion was at the
expected site.
To restore the deletion in ORF61, a plasmid contain-
ing ORF61 with additional flanking sequences was
obtained. Cosmid MstII A was cut with NgoMI and PstI
and the 4.2-kb fragment containing ORF61 was in-
serted into the NgoMI and PstI sites of plasmid
pGEM2 (Promega, Madison, WI). The resulting plas-
mid, pORF61, contains VZV nucleotides 101,627 to
105,768.
Plasmid pNotB was constructed by cutting cosmid
VZV NotI BD with NotI and cloning the 29-kb NotIB
fragment into the NotI site of pBluescript II (KS1)
(Stategene, LaJolla, CA). Plasmid pCMV62 contains
the VZV ORF62 immediate-early transactivator gene
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driven by the human cytomegalovirus IE promoter
(Perera et al., 1992).
Transfections
Melanoma cells or cell clones, stably transfected with
plasmid pSV2neo-ORF61 that had not been selected for
expression of ORF61, were used for transfection. Cos-
mids were linearized using NotI or Bsu36I and precipi-
tated. Plasmids pNotB and pCMV62 along with cosmids
VZV NotI A, MstIIB and MstII A, MstII A-61D, MstII A-61S
or MstII A-61d were transfected into melanoma cells as
described previously (Cohen and Seidel, 1993). Cells
were treated with trypsin and replated each week there-
after until CPE was detected.
To repair the deletion in viruses containing the ORF61
mutants, pORF61 was linearized and MeWo cells were
transfected with 0.5 mg of virion DNA from VZV
ROka61dA or ROka61DA, 1.5 mg of plasmid pORF61, and
50 ng of pCMV62. The transfected cells were passaged
into flasks after transfection and subsequently passaged
four times in schwannoma cells. Cell-free VZV was pre-
pared as described previously (Shiraki and Hyman,
1987).
Southern blots, immunoblots, and
immunoprecipitations
VZV DNA was purified from nucleocapsids and cut
with BamHI, NsiI, or BamHI and AscI and fractionated on
0.8% agarose gels. The DNA was transferred to nylon
membranes and probed with a [32P]dCTP-radiolabeled
2.7-kb BsmI fragment (VZV nucleotides 102,891 to
105,631) which contains ORF61.
Immunoblots were performed using rabbit antibody to
ORF61 (a kind gift from P. Kinchington (Ng et al., 1994) or
murine monoclonal antibody to VZV gE (Chemicon, Te-
mecula, CA). VZV-infected cell lysates were fractionated
on SDS–polyacrylamide gels, transferred to nitrocellu-
lose membranes, incubated with rabbit antiserum or
murine monoclonal antibody, washed, incubated with
horseradish peroxidase-conjugated anti-rabbit or anti-
mouse antibody, washed, and developed using en-
hanced chemiluminescence (Amersham Corp., Arlington
Heights, IL).
Immunoprecipitations were performed using lysates
from cells that had been infected with VZV and radiola-
beled for 3 h with [35S]methionine. The cells were then
washed and lysed in RIPA buffer (10 mM Tris–HCl, pH
8.0, 100 mM NaCl, 1 mM EDTA, 1% NP-40, 0.5% deoxy-
cholate, 0.1% SDS), and the supernatant was incubated
with a murine monoclonal antibody to VZV ORF62 protein
or gE (Chemicon). After addition of protein A–Sepharose,
immune complexes were washed in RIPA buffer and
fractionated on an SDS–polyacrylamide gel. Protein
bands were quantitated using a phosphorimager (Mo-
lecular Dynamics).
Immunofluorescent microscopy
Syncytia formation was examined by immunofluores-
cent microscopy as previously described (Mallory et al.,
1997) with the following modifications. Melanoma cells
were grown on glass coverslips and infected with VZV.
After 48 to 72 h the cells were washed in PBS, fixed with
2% paraformaldehyde in PBS for 10 min, washed in PBS
with 1% bovine serum, and permeabilized with 0.1% Tri-
ton X-100 in PBS for 10 min. After washing with PBS, the
cells were incubated for 1 h with BODIPY FL ceramide
(Molecular Probes, Inc., Eugene, Oregon), washed in
PBS, and examined by fluorescent microscopy. BODIPY
FL ceramide labels Golgi complexes with a fluores-
cein tag.
Growth studies of recombinant VZV
Growth curves of recombinant VZV were performed by
infecting cells with VZV-infected cells containing about
100 PFU of VZV. At 1, 2, 3, 4, and 5 days after infection, the
cells were treated with trypsin and serial dilutions were
used to infect MeWo cells. Plaques were counted 7 days
after infection. Plaques sizes for cells infected with VZV
mutants were measured microscopically. The mean size
of 20 plaques was determined and the Tukey multiple
comparison test was used to determine whether the
differences were significant.
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